Compare Bit Digital Inc (BTBT) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bit Digital Inc vs Gilead Sciences, Inc. — how do they compare? Bit Digital Inc trades at $1.66 (market cap $581.34M), while Gilead Sciences, Inc. trades at $129.86 (market cap $161.45B). The key difference: Gilead Sciences, Inc. is far larger — about 277.7× Bit Digital Inc's market cap, and Gilead Sciences, Inc. pays a 2.52% dividend while Bit Digital Inc pays none. Which is the better fit depends on your goals.
| BTBT | GILD | |
|---|---|---|
Market Cap | $581.34M | $161.45B |
Sector | Technology | Health |
52-Week High | $4.22 | $155.80 |
52-Week Low | $1.27 | $108.22 |
Enterprise Value | $870.65M | $175.98B |
Dividend Yield | — | 2.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BTBT trades at $1.64, down 2.96% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $80.32 million in 2025 with a -145.45% net income margin, missing earnings expectations for three consecutive quarters. Recent strategic moves include a $100 million loan facility for WhiteFiber and a $20 million Ethereum purchase to bolster its asset position.
Despite 100% analyst buy ratings, BTBT faces significant fundamental challenges with persistent losses and negative cash flow from operations. The stock's appeal hinges on turnaround execution and crypto market recovery, but high volatility and operational risks warrant caution for investors.
Gilead Sciences (GILD) trades at $131.40, up 1.21% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA approvals for Trodelvy in metastatic triple-negative breast cancer and ongoing Ebola antiviral trials highlight pipeline strength. Analyst consensus remains strongly positive with a $152.83 price target.
GILD presents a compelling investment case with strong profitability, expanding oncology portfolio, and 67% analyst buy ratings. Key risks include patent expirations on HIV drugs and volatile cash flow trends. The stock offers 16% upside to consensus target with dividend support, though investors should monitor pipeline execution and generic competition timelines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bit Digital Inc
Bit Digital is a sustainability-focused digital asset production company. It primarily engages in Bitcoin mining and Ethereum staking while also providing high-performance computing (HPC) infrastructure for AI applications.
Read more on BTBT →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
